Cobra  Biomanufacturing Plc (Keele, UK) has entered into a manufacturing development  agreement with GenVec, Inc. (Gaithersburg, MD) for TNFerade. The agreement will  cover technology transfer, scale-up, and validation of the manufacturing  process for TNFerade through cGMP consistency lots that will be produced at  Cobra's facility in Oxford, United Kingdom.

  TNFerade is  an adenovector, which contains the gene for tumor necrosis factor- alpha, an  immune system protein with potent and well-documented anticancer effects, for  direct injection into tumors. TNFerade is being developed for use in combination with radiation or  chemotherapy for the treatment of various cancers.

News

Cobra Biomanufacturing Plc (Keele, UK) has entered into a manufacturing development agreement with GenVec, Inc. (Gaithersburg, MD) for TNFerade.